EC Clinical and Medical Case Reports

Rhabdomyosarcoma (RMS) is a malignant neoplasm originating from undifferentiated myogenic progenitor cells, commonly diagnosed in the pediatric population, its incidence in adults is exceedingly rare. It mainly affects the cerebral and cervical regions, followed by the genitourinary tract.

the majority of genital tract rhabdomyosarcomas occur in the vagina, followed by the cervix and the uterine corpus, RMS of the cervix account for less than 1% of all cervix cancer, and approximately half of them are embryonic type, most commonly present in pre-pubertal or in reproductive age women in the second and third decade of life, rarely in postmenopausal patients.

The treatment ranges from radical surgery to conservative surgery, and neoadjuvant chemotherapy.

 Keywords: Embryonal Rhabdomyosarcoma; MRI; Uterine Cervix

1. Qiang JX., et al. “Sarcoma botryoides of the uterine cervix: a case report”. Journal of Obstetrics and Gynaecology Research 3 (1998): 197-201.
2. Ibrahim U and Saqib A. “Embryonal rhabdomyosarcoma of the cervix: a rare disease at an uncommon age”. Cureus11 (2017): e1864.
3. L Almusalam., et al. “Uterine cervix rhabdomyosarcoma: an uncommon entity in an adult patient”. BMJ Case Reports 13.11 (2020): e238596.
4. Pinto A and Kahn RM. “Uterine rhabdomyosarcoma in adults”. Human Pathology 74 (2018): 122-128.
5. Sung S and Abramovitz A. “Postmenopausal bleeding”. StatPearls Publisher Treasure Island, FL, USA (2021).
6. Saâdi I., et al. “Rhabdomyosarcome botryoïde du col utérin: à propos d’un cas Sarcoma botryoïde of the uterine cervix”. Cancer/Radiothérapie 6 (2002): 363-365.
7. Daya DA and Scully RE. “Sarcoma botryoides of the uterine cervix in young women: a clinicopathological study of 13 cases”. Gynecologic Oncology 3 (1988): 290-304.
8. Ferguson SE and Gerald W. “Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults”. American Journal of Surgical Pathology 3 (2007): 382-389.
9. Khosla D., et al. “Sarcomas of the uterine cervix: a united and multidisciplinary approach is required”. Womens Health (London, England)6 (2013): 501-504.
10. Wright JD., et al. “Cervical sarcomas: an analysis of incidence and outcome”. Gynecologic Oncology 2 (2005): 348-351.
11. Ricciardi E and Plett H. “Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series”. International Journal of Gynecological Cancer 1 (2020): 21-28.
12. El Amrani N., et al. “Tumeur rare du col utérin: le rabdomyosarcome à propos d'un cas”. Médecine du Maghreb 81 (2000).
13. Arndt CA and Donaldson SS. “What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?” Cancer12 (2001): 2454-2468.
14. Kobi M., et al. “Sarcoma botryoides: MRI findings in two patients”. Journal of Magnetic Resonance Imaging 3 (2009): 708-712.
15. Desar IM and Ottevanger PB. “Systemic treatment in adult uterine sarcomas”. Critical Reviews in Oncology/Hematology 122 (2018): 10-20.
16. Liu W and Jiang Q. “Advances of systemic treatment for adult soft-tissue sarcoma”. Chinese Clinical Oncology 4 (2018): 42.
17. Walterhouse DO., et al. “Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group”. Journal of Clinical Oncology 31 (2014): 3547-3553.